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1. Introduction
The epidemiology of HIV infection and viral hepatitis among injection drug users (IDUs) is
changing in western countries; reductions in the epidemic of blood-borne infections, such as
HIV infection, and viral hepatitis among drug users are probably related to the generaliza‐
tion of harm-reduction interventions and to the treatment of both HIV/AIDS and substance
abuse. Opioid substitution therapy for the treatment of patients with heroin dependence,
needle exchange programmes, access to Highly Active Antiretroviral Therapy (HAART)
and supervised injecting facilities, among other preventive interventions, have contributed
to reduce the impact of the HIV epidemic among drug users.
Surveillance of HIV infection in Spain is available in 15 out of the country’s 17 autonomous
regions. According to the National AIDS Programme, 2,264 new HIV infections were diag‐
nosed in 2009, which represents 79 cases per million of the population [1].
As previously reported [2], the beginning of the HIV epidemic in Spain was largely driven
by IDUs and the initial decrease in the rates of infection were reported more than a decade
ago [3]. In 2009, 77% of new HIV infections were reported as sexually transmitted and IDUs
represented less than 8% of cases [1].
The HIV epidemic among IDUs continues to develop differently across different parts of Eu‐
rope. In the European Union, the reported rates of newly diagnosed cases of HIV infection
in IDUs are mostly stable or in decline [4]. Data on newly reported cases of HIV infection in
IDUs for 2009 suggest that rates of infection are still declining in Europe, following a peak in
2002, which was due to outbreaks in eastern countries. Reductions in the rates of HIV infec‐
tion in IDUs are partially the result of better preventive interventions and access to care
© 2013 Sanvisens et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
[5,6], however, Spain is one of the western European countries reporting high rates of newly
diagnosed HIV infection among IDUs between 2004 and 2009 (Figure 1)[4].
Figure 1. Newly diagnosed HIV infections among IDUs from Europe and central Asia in 2009. Source: Annual Report
2011, European Monitoring Centre for Drugs and Drug Addiction(4).
Several studies have shown that IDUs are at increased risk of sexually transmitted HIV in‐
fection [7,8] and other authors have shown higher rates of HIV infection among recent and
younger IDUs [9,10].
Non-injecting drug users (non-IDUs) are not exposed to blood-borne infections, but remain
at risk of sexually transmitted diseases including HIV. Some studies have found a relation‐
ship between non-IDU and the increased risk of HIV and other sexually transmitted diseas‐
es [11,12]. Moreover, there have been reports on the causal relationship between alcohol
drinking and the risk of HIV infection [13-15].
1.1. Hepatitis B and C
About 80% of individuals exposed to hepatitis C virus (HCV) infection and 5% of adults ex‐
posed to hepatitis B virus (HBV) infection develop chronic liver disease. Cirrhosis and hepa‐
tocellular carcinoma are the most important sequelae of these infections [16].
It is well known that HCV infection is highly prevalent among drug users and that many
IDUs contract the infection early in the course of injecting drugs; this implies that there may
be only a small time window for initiating preventive interventions to reduce transmission
of HCV infection.
About 10 million IDUs (range 6.0-15.2 million) worldwide were anti-HCV positive in 2010
and 1.2 million IDUs (range 0.3-2.7 million) were HBV infected (HBsAg positive). Geograph‐
ical differences exist in the distribution of blood-borne infections among drug users and
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eastern Europe, east Asia and southeast Asia have the largest populations of IDUs infected
with viral hepatitis [4,17].
Two major risk factors for HBV infection include the IDU his/herself and unprotected sex
[18-21]. Studies among drug users from the United States have shown that 70% of cases are
infected within five years of initiating drug use [22] and that 38%-89% of IDUs from Europe
and North America have markers of HBV infection in cross-sectional studies [23].
In 2004, 16% of acute viral hepatitis reported to the Center for Disease Control in the United
States had recent use of injected drugs as a risk factor [24].
In any case, the epidemiology of hepatitis B virus infection in drug users and other subpo‐
pulations at risk may vary according to the extent of preventive immunization; in Spain, the
first selective hepatitis B vaccination programme began in 1984 [25].
In this study among IDUs and non-IDUs seeking treatment of substance abuse in Barcelona,
Spain, we aimed to analyse trends in the epidemiology of HIV, HCV and HBV infections.
2. Patients and methods
2.1. Setting and study population
Prospective study in a cohort of patients admitted to substance abuse treatment pro‐
grammes in three teaching hospitals between January 1997 and December 2006. The treat‐
ment units are located in Barcelona (Hospital del Mar), Badalona (Hospital Universitari
Germans Trias i Pujol) and L’Hospitalet de Llobregat (Hospital Universitari de Bellvitge).
Patients admitted to treatment were referred from primary care centres and the principal
criterion for admission was the severity of addiction. Patients were required to be older than
18 years and the main objective of admission was to control signs and symptoms of with‐
drawal. Upon admission, we collected socio-demographic characteristics, the history of sub‐
stance abuse (main drug, age at first drug use, route of administration, history of opioid
substitution treatment) and blood samples to test for HIV infection, HCV infection and HBV
(HBcAb) infection, as previously reported [26,27].
The blood samples were tested by Enzyme ImmunoAssay (EIA) for antibodies to HIV infec‐
tion and the results were confirmed by Western blot.
At discharge, patients were referred to their primary care providers. Pharmacological treat‐
ment was recommended in the majority of cases and all patients were advised to continue
with medical visits at the outpatient clinics.
For the purposes of this study, patients who were admitted more than once between 1997
and 2006 were analysed only with regard to the first admission. Similarly, data from two
hospitals were controlled so that no duplicate patients existed.
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All the participants gave their consent for the determination of HIV and hepatitis serology.
The methods utilized to perform this study complied with ethical standards for medical re‐
search and with principles of good clinical practice.
2.2. Statistical analysis
Bivariate analyses were performed on the characteristics of patients according to the route of
drug administration: 1) non-IDU patients were defined as those individuals without a histo‐
ry of injection drug use; 2) IDU patients were defined as those with current or past use of
intravenous drug use. The bivariate analyses included the χ2 Pearson test for categorical var‐
iables and Student’s t test for continuous variables.
Prevalent cases correspond to patients that tested HIV, HCV or HBV-positive at admission.
Incident cases were defined as those HIV-seronegative patients at admission that subse‐
quently became HIV-positive during follow-up.
We carried out a direct measurement of HIV incidence based on the follow-up of the initial‐
ly HIV-seronegative patients. However, due to the relatively low percentage (44%) of pa‐
tients that underwent new HIV tests, we used a sensitivity analysis in a scenario based on
the absence of new infections among those not re-tested for HIV infection during follow-up.
Sensitivity analysis is useful in predicting the outcome of a decision if a situation turns out
to be different compared to that which was previously assumed. By creating a given set of
scenarios, the method can determine how changes in one variable will impact on the results.
All incidence rates were calculated in person-years with the number of HIV infections (inci‐
dent cases) in the numerator and the sum of follow-up times in the denominator.
Joinpoint regression models were fitted to analyse changes in trends of HIV and viral hepa‐
titis over time. These models evaluate changes that are produced on a logarithmic scale with
a binomial distribution for the prevalence of infection and a Poisson distribution for the inci‐
dence of infection.
Descriptive analyses of the data were performed with STATA, version 8.0 (Stata Corp., Col‐
lege Station, TX, USA). For the Joinpoint regression models, we used the US National Can‐
cer Institute’s Joinpoint Regression Program software [28].
P values less than 0.05 (p<0.05) were considered statistically significant.
3. Results
3.1. Characteristics of the study population
Between January 1997 and December 2006 there were 3,318 admissions corresponding to
2,488 patients, of which 2,432 were eligible. Median age at admission was 34 years (IQR: 29 -
40 years) and 78.7% were men. A total of 925 (38%) patients were non-IDUs and 1,507 (62%)
were current or past IDUs.
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The baseline characteristics of the patients according to the antecedent of IDU/non-IDU are
presented in Table 1. The majority of non-IDUs cases were patients with alcohol use disorders.
The main drug of abuse in IDUs patients was opiates (57.8%) and the median duration of
drug abuse was 12 years (IQR:5 – 17 years); 28.9% of them were receiving methadone at ad‐
mission. Non-IDU patients were significantly older (37 years, IQR 30 – 45 years) than in IDU
(32 years, IQR 28 – 37 years) (p<0.05). The non-IDU were admitted mostly (65.1%) during
the 2002 – 2006 period, whereas IDUs were admitted mostly (63%) during the 1997 – 2001
period (p<0.05). As expected, the prevalence of HCV infection was significantly higher in
IDUs (86.6%) than in non-IDUs (9.7%) (p< 0.05). In this sense, the prevalence of hepatitis B
virus infection (HBcAb-positive) was significantly higher in IDUs (56.8%) than in non-IDUs
(17.7%) (p<0.05) (Table 1).
Non-IDU IDU
p-valueN=925 N=1507
N (%) n (%)
Male 726 (78.5) 1188 (78.8) 0.840
Age median [IQR] 37 [30-45] 32 [28-37] <0.05
Year of admissionmedian [IQR] 2003 [2000-2005] 2000 [1998-2003] <0.05
Period of admission
1997-2001
2002-2006
323 (34.9)
602 (65.1)
949 (63.0)
558 (37.0) <0.05
Duration of drug abuse, years
(n=1888) median [IQR] 10 [5-18] 12 [5-17] 0.079
HIV positive 26 (2.8) 636 (42.2) <0.05
HCV positive (n=2394) 88 (9.7) 1284 (86.6) <0.05
HBcAb positive (n=1890) 136 (17.7) 636 (56.8) <0.05
Main drug of abuse (n=2421)
Opiates
Alcohol
Other
231 (25.1)
432 (46.9)
258 (28.0)
867 (57.8)
124 (8.3)
509 (33.9) <0.05
Antecedent of imprisonment (n=2291) 168 (19.4) 716 (50.2) <0.05
Methadone* (n=1499) 46 (7.7) 261 (28.9) <0.05
* Available in two hospitals
Table 1. Characteristics of IDU and non-IDU patients admitted to substance abuse treatment programmes in the
Barcelona area, Spain, 1997-2006.
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3.2. HIV infection
Table 2 shows the prevalence and incidence of HIV infection in non-IDUs according to the
year of admission. Regarding HIV prevalence, 2.8% (95% CI: 1.8-4.1) of patients were HIV-
positive at admission with the highest prevalence of infection observed in 1999 (8.3%).
Among the 899 non-IDU, HIV-negative patients, 364 (40.5%) were followed-up for a median
of 2.3 years (IQR: 0.9 – 4.1 years; 1060 p-y); only five patients acquired HIV infection during
follow-up (incidence rate 0.47 x 100 p-y; 95% CI: 0.2-1.1).
The prevalence of HIV in IDUs was 42.2% (636/1507). The highest prevalence was observed
in 1997 (45.1%) and the lowest in 2006 (32.1%).
Among the 871 IDUs, HIV-negative patients, 47.1% were followed for a median of 2.7 years
(IQR: 1.2 - 5.2 years, 1415.5 p-y) and 36 acquired HIV infection (incidence rate 2.54 x 100 p-y
(95% CI: 1.8-3.5); the highest rate of infection was observed in 1999 (3.7 x 100p-y). Patients
followed-up were similar to those not followed regarding the proportion of male/female, the
main drug of abuse and the prevalence of HCV infection and HBV (HBcAb) infection.
HIV PREVALENCE HIV INCIDENCE
Patients
at risk
Patients
followed P-Y
Incident
cases Incident rate
n (%) 95% CI n (%) x100 p-y 95% CI
1997 0 (0.0) -- 51 24 (47.1) 13.7 0 0.00 --
1998 2 (3.3) (0.4-11.3) 59 30 (50.8) 37.8 1 2.65 (0.4-18.8)
1999 5 (8.3) (2.8-18.4) 55 25 (45.5) 52.1 0 0.00 --
2000 2 (2.7) (0.3-9.4) 72 24 (33.3) 71.1 0 0.00 --
2001 1 (1.3) (0.03-7.0) 76 34 (44.7) 93.9 0 0.00 --
2002 4 (3.9) (1.1-9.6) 99 44 (44.4) 112.8 0 0.00 --
2003 2 (1.7) (0.2-6.0) 116 50 (43.1) 138.3 1 0.72 (0.1-5.1)
2004 3 (2.5) (0.5-7.0) 119 50 (42.0) 170.1 1 0.59 (0.1-4.2)
2005 3 (2.5) (0.5-7.0) 118 35 (29.7) 184.9 1 0.54 (0.1-3.8)
2006 4 (2.9) (0.8-7.2) 134 48 (35.8) 185.3 1 0.54 (0.1-3.8)
1997-2006 26 (2.8) (1.8-4.1) 899 364 (40.5) 1060 5 0.47 (0.2-1.1)
Table 2. HIV serial prevalence and HIV serial incidence among non-IDUs by year of admission to substance abuse
treatment programmes in the Barcelona area, Spain, 1997-2006.
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Table 3 shows the prevalence and incidence of HIV infection in IDUs according to the year
of admission, ultimately showing values slightly lower than the rates registered since 1999.
Trends of HIV prevalence in non-IDUs is shown in the upper part of Figure 2 (Graphic A).
Overall, changes in HIV prevalence were not statistically significant, in spite of the model
indicating a decrease in prevalence over time (p=0.24).
In terms of HIV incidence (Figure 2, Graphic B), the model shows statistically significant dif‐
ferences over time (p=0.004).
The trend of HIV prevalence in IDUs showed a significant (p=0.01) decline between 1997
and 2006 (Figure 3, Graphic A). With respect to HIV incidence among IDUs, no changes
in the trends of infection rate were detected after adjusting the regression model (p=0.944)
(Figure 3, Graphic B).
HIV PREVALENCE HIV INCIDENCE
Patients
at risk
Patients
followed P-Y
Incident
cases Incident rate
n (%) 95% CI n (%) x100 p-y 95% CI
1997 124 (45.1) (39.1-51.2) 151 84 (55.6) 45.3 1 2.21 (0.3-15.7)
1998 84 (43.5) (36.4-50.8) 109 63 (57.8) 102.4 2 1.95 (0.5-7.8)
1999 83 (44.4) (37.1-51.8) 104 52 (50.0) 133.3 5 3.75 (1.6-9.0)
2000 71 (41.8) (34.3-59.6) 99 47 (47.5) 153.5 3 1.95 (0.6-6.1)
2001 53 (42.7) (33.9-51.9) 71 29 (40.8) 163.3 4 2.45 (0.9-6.5)
2002 59 (38.6) (30.8-46.8) 94 35 (37.2) 168.9 3 1.77 (0.6-5.5)
2003 50 (42.7) (33.6-52.2) 67 31 (46.3) 174.0 6 3.45 (1.5-7.7)
2004 53 (42.7) (33.9-51.9) 71 31 (43.7) 175.6 5 2.85 (1.2-6.8)
2005 34 (39.5) (29.1-50.7) 52 21 (40.4) 160.4 4 2.49 (0.9-6.6)
2006 25 (32.1) (21.9-43.6) 53 17 (32.1) 138.8 3 2.16 (0.7-6.7)
1997-2006 636 (42.2) (39.7-44.7) 871 410 (47.1) 1415.5 36 2.54 (1.8-3.5)
Table 3. HIV serial prevalence and HIV serial incidence in IDUs by year of admission to substance abuse treatment
programmes in the Barcelona area, Spain, 1997-2006.
In sensitivity analysis, the rate of HIV infection among non-IDUs was 0.19x100 p-y (95% CI:
0.07-0.45) and 1.08 x100p-y (95% CI: 0.5-1.5) among IDUs.
In sensitivity analysis, trends of HIV incidence for non-IDU patients remained unchanged
with respect to the direct method. However, HIV incidence for IDUs significantly decreased
over time in the best scenario (no new infections among those lost to follow-up, p=0.04).
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3.3. Viral hepatitis
The prevalence of HCV infection and HBV (HBcAb) infection in non-IDUs was 9.7%, and
17.7%, respectively. The prevalence of HCV in the years analysed oscillated between 6.8%
and 15.6%, but differences were not statistically significant (p=0.589) (Figure 4, Graphic A).
As expected, the prevalence of HCV infection in IDUs was high (86.6%) and changes over
the years analysed were negligible (p=0.240) (Figure 5, Graphic A).
The prevalence of HBV (HBcAb) infection in non-IDUs oscillated between 8.3% and 22.9%,
and changes over time were not statistically significant (p=0.696) (Figure 4, Graphic B). HBV
(HBcAb) infection was observed in 56.8% of IDUs, which oscillated between 48.8% and
64.3% in the years analysed. Analysis of the trend did not show statistically significant dif‐
ferences during the period analysed (p=0.218) (Figure 5, Graphic B).
 
Graphic B 
Graphic A 
Figure 2. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in non-IDU patients admitted to sub‐
stance abuse treatment programmes in the Barcelona area, Spain, 1997- 2006.
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 Graphic B 
Graphic A 
Figure 3. Trends in HIV prevalence (Graphic A) and HIV incidence (Graphic B) in IDUs admitted to substance abuse
treatment programmes in the Barcelona area, Spain, 1997- 2006.
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 Graphic B 
Graphic A 
Figure 4. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in non-IDUs admitted to treatment
programmes in the Barcelona area, Spain, 1997- 2006.
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 Graphic B 
Graphic A 
Figure 5. Prevalence of HCV infection (Graphic A) and HBV infection (Graphic B) in IDUs admitted to treatment pro‐
grammes in the Barcelona area, Spain, 1997- 2006.
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4. Discussion
Results from this cohort of patients seeking substance abuse treatment indicate that drug
users, irrespective of the main route of drug administration, are at increased risk of HIV in‐
fection and viral hepatitis. In fact, the prevalence of HIV infection and HCV infection in non-
IDU patients is 2.8% and 9.7%, respectively. Several studies analysing risky sexual
behaviour of drug and alcohol abusers suggest an association between cocaine, ampheta‐
mines or alcohol abuse and the sexual transmission of HIV [19-24], which could explain the
relatively high prevalence of HIV infection among non-IDU patients from this study [29-34].
Despite the relatively high prevalence of HIV infection, there was a trend in the decline of
HIV incidence among the non-IDUs. To some extent, the incidence of HIV infection was low
(0.47 per 100 p-y) and the results shown here indicate that non-IDUs have a fivefold lower
risk of HIV than the IDUs, as shown in a previous study [35].
The observed decline in the prevalence of HIV infection among IDUs is likely the result of
some preventive interventions introduced in Spain at the beginning of 1990s. Harm-reduc‐
tion interventions to reduce the impact of the HIV epidemic associated with heroin depend‐
ence included the access to opioid substitution therapy with methadone and the needle
exchange programmes, among other interventions. Our findings indicate that HIV infection
among IDUs from metropolitan Barcelona has stabilized and that rates of new infections are
moderate with respect to reports from other cities [36-38]. In addition, our results agree with
those reported nationally, indicating that sexual transmission now represents 80% of new
HIV infections in Spain [39]. Further, our results show that the proportion of IDUs being ad‐
mitted for substance abuse treatment is declining, suggesting a decrease in the number of
IDUs in Spain [40].
Data from European countries show tendencies toward a low rate of HIV infection in drug
users. For example, Poland, Finland and Germany have considerably reduced the rates of
infection to two cases per million inhabitants in 2007 [41]. In this study, we determined an
overall rate of infection of 2.54 per 100 p-y between 1997 and 2006, which is similar to that
observed in other studies [6].
In contrast, the decline in the prevalence of HIV infection is not accompanied by a decline in
HCV prevalence [42,43]. This observation suggests that IDUs still maintain non-sterile injec‐
tion practices. The HIV and hepatitis C virus are transmitted primarily by large or repeated
direct percutaneous exposures to contaminated blood. In Spain, IDU is a factor in 28% of all
contemporary AIDS cases and it accounts for more than 60% of new hepatitis C infections in
Europe and the USA [1,44].
It is well known that the majority of IDUs become infected with hepatitis C during their first
year of injecting and that because of its infectivity HCV spreads more rapidly than HIV
[45,46,47].
In this study, the prevalence of HBV is high. A recent systematic review suggests that
worldwide around 1.2 million IDUs are chronic carriers of HBV infection and that the pat‐
Current Perspectives in HIV Infection378
tern of infection shows clear geographical differences [17]. In fact, rates of HBcAb-positive
varied widely between countries from 4.2% in Slovenia to 85.0% in Mexico [17].
Because of the high rate of both HCV and HBV infection, the probability of coinfection in
IDUs is high. In this sense, vaccination against HBV must be prioritized for all susceptible
drug users.
There are several limitations to this study that need to be mentioned. First of all, a propor‐
tion of patients, HIV-seronegative, were not re-tested for HIV infection during follow-up de‐
spite the fact that many of them were regularly visited in their primary care centres; in this
sense, assessment of risk behaviour and awareness of drug use disorders by health care pro‐
fessionals are key components for developing preventive interventions. Second, in this
study assessment of HBV infection was limited to one marker of infection; in other words,
more accurate estimation of chronic carriers of HBV infection, susceptibility to infection or
immunization due to HBV vaccination was not available. For the HCV pattern of infection
we only analysed antibodies against HCV and RNA-HCV was not available; it is well
known that a minority (10-15%) of the individuals infected with HCV clear the virus during
the natural history of the disease. Third, in this study we did not analyse the impact of sexu‐
al transmission of HIV and viral hepatitis on the results shown here. In this sense, drug-ad‐
dicted women have been reported to have a higher risk of HIV infection than drug-addicted
men [48].
In contrast, the strength of this cross-sectional and longitudinal study is based on data col‐
lected at three centres that provide clinical care and treatment for the majority of severe
drug addicts in Barcelona and its metropolitan area. Having data from the three hospitals
adds external validity to the results and may reflect changes in the epidemiology of HIV and
viral hepatitis in young adults seeking treatment for substance abuse in an urban area.
In summary, since 1997 we observed a significant decline in the prevalence of HIV infection
in IDUs, however, background prevalence of HIV and viral hepatitis is still high thus sug‐
gesting that prevention efforts and treatment of substance abuse are necessary to further re‐
duce transmission of blood-borne infections in this population.
Nomenclature
HIV= Human Immunodeficiency Virus.
IDU= Injecting Drug User.
AIDS= Acquired Immunodeficiency Syndrome.
HAART= Highly Active Antiretroviral Therapy.
HCV= Hepatitis C virus.
HBV= Hepatitis B virus.
HBsAg= Surface Antigen of Hepatitis B Virus.
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HBcAb= Hepatitis B core Antibody.
EIA= Enzyme Immunoassay.
IQR= Interquartile Range.
CI= Confidence Interval.
RNA= Ribonucleic Acid
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